ACHV | Achieve Life Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.3300 - 2.6300
52 Week Range	1.8400 - 5.59
Beta	1.28
Implied Volatility	141.94%
IV Rank	90.68%
Day's Volume	218,350
Average Volume	199,427
Shares Outstanding	34,685,100
Market Cap	90,181,260
Sector	Healthcare
Industry	Biotechnology
IPO Date	1995-10-12

Valuation
Profitability
Growth
Health
P/E Ratio	-2.10
Forward P/E Ratio	N/A
EPS	-1.24
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	22
Country	Canada
Website	ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

ACHV's peers: VECT, ICVX, APLS, ITOS, TCRX, DAWN, ABOS, XFOR, INZY, IMMX, CNSP, HEPA, FRLN, AVRO, NXTC, CTMX, NLTX, SPRO, ASMB, BOLT, CHRS, GRCL, BRTX

*Chart delayed

Analyzing fundamentals for ACHV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ACHV Fundamentals page.

Watching at ACHV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ACHV Technicals page.